Company Description
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding.
Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington’s disease.
The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease.
It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering.
uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Country | Netherlands |
Founded | 1998 |
IPO Date | Jun 20, 2007 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 209 |
CEO | Matthew Kapusta |
Contact Details
Address: Paasheuvelweg 25 Amsterdam, 1105 BP Netherlands | |
Phone | 31 20 240 6000 |
Website | uniqure.com |
Stock Details
Ticker Symbol | QURE |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001590560 |
CUSIP Number | N90064101 |
ISIN Number | NL0010696654 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Matthew Craig Kapusta CPA | Chief Executive Officer and Executive Director |
Christian Klemt | Chief Financial Officer, Principal Financial Officer and GM of Amsterdam Site |
Richard Porter Ph.D. | Chief Business and Scientific Officer |
Dr. Jeannette Potts J.D., Ph.D. | Chief Legal and Compliance Officer and Corporate Secretary |
Prof. Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany |
Dr. Amin Abujoub Ph.D. | Chief Technical Operations Officer |
Dr. Tamara Tugal Ph.D., MBA | Business Development Director |
Erin Boyer | Chief People and Culture Officer |
Dr. Walid Abi-Saab M.D. | Chief Medical Officer |
Eileen Sawyer | Vice President of Global Medical Affairs |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 27, 2025 | 10-K | Annual Report |
Feb 27, 2025 | 8-K | Current Report |
Feb 14, 2025 | SCHEDULE 13G/A | Filing |
Jan 8, 2025 | 8-K | Current Report |
Jan 8, 2025 | 424B5 | Filing |
Jan 7, 2025 | 424B5 | Filing |
Jan 7, 2025 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
Dec 17, 2024 | SCHEDULE 13G | Filing |
Dec 10, 2024 | 144 | Filing |
Dec 10, 2024 | 8-K | Current Report |